Based on the evidence that HIF-1α inhibition promotes NK cell function, permanently inhibiting HIF-1α expression in NK cells could be a useful cancer immunotherapy modality compared to transiently inhibiting HIF-1α using drugs such as the small-molecular compound KC7F2 [23]. Here, HIF1A is linked to cancer.